Richard C. Mulligan, Ph.D., (born 1954) is the Mallinckrodt Professor of Genetics at Harvard Medical School, and Director of the Harvard Gene Therapy Initiative. He is a Director of Enzon Pharmaceuticals, Inc., and Biogen Idec, Inc.

Awards

* 1981 MacArthur Fellows Program * 1983 Searle Scholar Program

Works

* Lindemann, D., Patriquin, E., Feng, S. and Mulligan, R.C. 1997 "Versatile retovirus vector systems for regulated gene expression in vitro and in vivo". ''Molecular Medicine'' 3:466-476. * Goodell, M.A., Rosenzweig, H-.K., Marks, D.G., DeMaria, M., Paradis, G., Grupp, S.A., Sieff, C.A., Mulligan, R.C. and Johnson, R.P. 1997. "Dye efflux studies suggest the existence of CD34-negative/low hematopoietic stem cells in multiple species". ''Nature Medicine'' 3:1337–1345. * Mach, N., Lantz, C.S., Galli, S.J., Reznikoff, G., Mihm, M., Small, C., Granstein, R., Beissert, S., Sadelain, M., Mulligan, R.C. and Dranoff, G. 1998. "Involvement of interleukin-3 in delayed-type hypersensitivity". ''Blood'' 92:778-783.

References

External links

"Richard C. Mulligan", ''Google Scholar''
{{DEFAULTSORT:Mulligan, Richard C. 1954 births MacArthur Fellows Harvard Medical School faculty Living people